BR0016652A - Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo - Google Patents

Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo

Info

Publication number
BR0016652A
BR0016652A BR0016652-9A BR0016652A BR0016652A BR 0016652 A BR0016652 A BR 0016652A BR 0016652 A BR0016652 A BR 0016652A BR 0016652 A BR0016652 A BR 0016652A
Authority
BR
Brazil
Prior art keywords
amyloid angiopathy
cerebral amyloid
individual
methods
treat
Prior art date
Application number
BR0016652-9A
Other languages
English (en)
Inventor
Allan M Green
Francine Gervais
Original Assignee
Neurochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem Inc filed Critical Neurochem Inc
Publication of BR0016652A publication Critical patent/BR0016652A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODOS PARA INIBIR ANGIOPATIA AMILóIDE CEREBRAL PARA TRATAR UM ESTADO DE DOENçA CARACTERIZADO POR ANGIOPATIA AMILóIDE CEREBRAL EM UM INDIVìDUO, E PARA DIAGNOSTICAR ANGIOPATIA AMILóIDE CEREBRAL EM UM INDIVìDUO". A invenção proporciona métodos para inibir angiopatia amilóide cerebral. A invenção proporciona adicionalmente métodos para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivíduo.
BR0016652-9A 1999-12-23 2000-12-22 Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo BR0016652A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17187799P 1999-12-23 1999-12-23
PCT/IB2000/002078 WO2001085093A2 (en) 1999-12-23 2000-12-22 Compounds and methods for modulating cerebral amyloid angiopathy

Publications (1)

Publication Number Publication Date
BR0016652A true BR0016652A (pt) 2002-11-19

Family

ID=22625484

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016652-9A BR0016652A (pt) 1999-12-23 2000-12-22 Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo

Country Status (11)

Country Link
US (2) US6670399B2 (pt)
EP (1) EP1251837A2 (pt)
JP (1) JP2003532656A (pt)
KR (3) KR20090016517A (pt)
CN (1) CN1434706A (pt)
AU (1) AU8431301A (pt)
BR (1) BR0016652A (pt)
CA (1) CA2395314A1 (pt)
IL (1) IL150374A0 (pt)
MX (1) MXPA02006196A (pt)
WO (1) WO2001085093A2 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
EP1237547A2 (en) * 1999-07-09 2002-09-11 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US20070135337A2 (en) * 1999-11-29 2007-06-14 Neurochem (International) Limited Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases
EP1251837A2 (en) * 1999-12-23 2002-10-30 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy
US7311893B2 (en) * 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
WO2003074008A2 (en) * 2002-03-01 2003-09-12 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
AU2003292936A1 (en) * 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1477493A1 (en) * 2003-05-15 2004-11-17 Bayer HealthCare AG Isotope coded affinity tags
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
BRPI0411800A (pt) * 2003-06-23 2006-08-08 Neurochem Int Ltd candidatos a fármacos e métodos para sua preparação
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20060079578A1 (en) * 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
EP1644325A2 (en) * 2003-06-23 2006-04-12 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7262223B2 (en) 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
EP1841460A2 (en) * 2004-06-18 2007-10-10 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
CN101035523A (zh) 2004-07-09 2007-09-12 西格马-奥利奇有限公司 旋光增加的手性离子液体
US8168830B2 (en) 2004-07-23 2012-05-01 Sigma-Aldrich Co. Llc High stability diionic liquid salts
JP5806440B2 (ja) 2004-07-23 2015-11-10 シグマ−アルドリッチ・カンパニー、エルエルシー 高安定性の二イオン液体塩
US20090215717A1 (en) * 2004-08-05 2009-08-27 Ivax Drug Research Institute Ltd. Sulfated oligosaccharides
CN101103018A (zh) * 2004-11-16 2008-01-09 神经化学（国际）有限公司 治疗cns和淀粉样蛋白-相关疾病的化合物
US20080025962A1 (en) * 2004-11-30 2008-01-31 Angesmg,Inc. Remedy for Alzheimer's Disease
BRPI0519243A2 (pt) * 2004-12-22 2009-01-06 Neurochem Int Ltd mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
CA2611586A1 (en) * 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2007023389A2 (en) * 2005-07-21 2007-03-01 Neurochem (International) Limited Polymorphic forms of 3-amino-1-propanesulfonic acid
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
MX2008008213A (es) * 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
US8188046B2 (en) * 2006-10-16 2012-05-29 University Of South Florida Amyloid beta peptides and methods of use
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
JP2010513219A (ja) * 2006-12-22 2010-04-30 ベラス ヘルス （インターナショナル） リミテッド 腎臓の疾患、糖尿病性腎症及び脂質代謝異常の治療
US8097721B2 (en) 2007-01-31 2012-01-17 Sigma-Aldrich Co. Llc High stability polyionic liquid salts
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US7618944B2 (en) * 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
GB0708507D0 (en) * 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
JP2010535193A (ja) * 2007-08-01 2010-11-18 サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク セエンエールエス チオホスフィン（チオホスホン）酸誘導体およびそれらの治療適用
US20090076167A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched tramiprosate
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
US8231895B2 (en) 2008-05-22 2012-07-31 Universidade De Coimbra Targeted delivery to human diseases and disorders
EP2180003A1 (en) * 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
US9023767B2 (en) * 2009-05-07 2015-05-05 Memorial Sloan-Kettering Cancer Center γ-Secretase substrates and methods of use
MX2012001671A (es) * 2009-08-10 2012-04-30 Bellus Health Inc Metodos, compuestos y composiciones para la administracion de acido 1,3-propanedisulfonico.
EP2289900A1 (en) * 2009-08-26 2011-03-02 Humboldt Universität zu Berlin Bisphosphonates as inhibitors of acid sphingomyelinase
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
CN103502466A (zh) 2010-09-07 2014-01-08 斯隆－凯特林纪念癌症中心 用于γ-分泌酶测定的方法和组合物
US12085575B2 (en) 2011-12-01 2024-09-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for detecting proteinopathies
US9599626B2 (en) * 2011-12-01 2017-03-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic and diagnostic method for ataxia-telangiectasia
US10962553B2 (en) 2011-12-01 2021-03-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for detecting proteinopathies
WO2013158846A1 (en) * 2012-04-20 2013-10-24 Baylor College Of Medicine Novel dxr inhibitors for antimicrobial therapy
CN102793694B (zh) * 2012-08-14 2014-06-04 武汉华纳联合药业有限公司 3-氨基-1-丙烷磺酸及其衍生物在制备治疗脑卒中的药物中的应用
JP5804463B2 (ja) 2012-12-27 2015-11-04 国立研究開発法人科学技術振興機構 環状ペプチド及びこれを含有する医薬
CN114805211B (zh) 2017-03-21 2024-08-23 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
ES3003810T3 (en) * 2017-04-17 2025-03-11 Univ Kyoto Optically-active 2-amino-phosphonoalkane acid, optically-active 2-amino-phosphonoalkane acid salt, and hydrates of these
RU2696684C1 (ru) * 2018-09-18 2019-08-05 Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) Способ определения типов когнитивных расстройств у больных церебральной микроангиопатией
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1140049A (en) 1977-12-22 1983-01-25 Dke J.E. Helgstran Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US4540564A (en) 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
WO1994022437A2 (en) 1993-03-29 1994-10-13 Queen's University At Kingston Method for treating amyloidosis
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5972328A (en) 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
US5455044A (en) 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
WO1994027602A1 (en) 1993-06-01 1994-12-08 Cortex Pharmaceuticals, Inc. Use of metabotropic receptor agonists in progressive neurodegenerative deseases
AU686277B2 (en) 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
WO1995022963A1 (en) * 1994-02-28 1995-08-31 Medinova Medical Consulting Gmbh Drug targeting system, method for preparing same and its use
US6168776B1 (en) * 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US5514653A (en) 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
DE4434654C2 (de) 1994-09-28 1996-10-10 Arburg Gmbh & Co Verfahren zur Beeinflussung zyklisch ablaufender Prozesse
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
JP2001505204A (ja) 1996-11-22 2001-04-17 エラン・ファーマシューティカルズ・インコーポレイテッド Ｎ―（アリール／ヘテロアリールアセチル）アミノ酸エステル、それを含有する医薬組成物および該化合物を用いてβ―アミロイドペプチドの放出および／または合成を阻害する方法
CA2272433A1 (en) 1996-11-22 1998-05-28 James E. Audia N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and methods for inhibiting beta-amyloid peptide release and/or its synthesis
AR009655A1 (es) * 1996-12-10 2000-04-26 Novartis Ag Una composicion parenteralmente inyectable, un metodo para su preparacion, metodos para el tratamiento de enfermedades, una modificacion decristal de 1-decansulfonato de desferrioxamina, su uso, un proceso para la produccion de dicha modificacion de cristal y una preparacion farmaceutica que
AU5727798A (en) * 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
IL134619A0 (en) 1997-08-18 2001-04-30 Univ Kingston Phosphono-carboxylate compounds for treating amyloidosis
US5869469A (en) 1997-08-18 1999-02-09 Queen's University At Kingston Phosphonocarboxylate compounds for treating amyloidosis
AU9125798A (en) * 1997-08-28 1999-03-16 University Of Washington Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
CA2320224C (en) 1998-02-11 2008-08-12 Neurochem, Inc. Method for modulating macrophage activation
WO1999059571A1 (en) 1998-05-15 1999-11-25 Neurochem, Inc. Use of amyloid inhibitors for modulating neuronal cell death
DK1083889T3 (da) * 1998-06-01 2004-04-13 Ortho Mcneil Pharm Inc Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
US6586475B1 (en) 1998-11-20 2003-07-01 Takeda Chemical Industries, Ltd. β-amyloid protein production/secretion inhibitors
ATE384077T1 (de) 1999-05-05 2008-02-15 Neurochem Int Ltd Stereoselektive antifibrillogene peptide
EP1251837A2 (en) * 1999-12-23 2002-10-30 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy

Also Published As

Publication number Publication date
US20030003141A1 (en) 2003-01-02
EP1251837A2 (en) 2002-10-30
JP2003532656A (ja) 2003-11-05
AU8431301A (en) 2001-11-20
WO2001085093A3 (en) 2002-08-29
WO2001085093A2 (en) 2001-11-15
IL150374A0 (en) 2002-12-01
CA2395314A1 (en) 2001-11-15
KR20020063266A (ko) 2002-08-01
CN1434706A (zh) 2003-08-06
US20080317834A1 (en) 2008-12-25
KR20090016517A (ko) 2009-02-13
US6670399B2 (en) 2003-12-30
KR20080003945A (ko) 2008-01-08
MXPA02006196A (es) 2002-12-09
WO2001085093A9 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
BR0016652A (pt) Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo
BR0111601A (pt) Método para o tratamento de doença cardiovascular
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
ATE374029T1 (de) Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
DK1287364T3 (da) Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
BR0116792A (pt) Derivados de diamina de triazol substituìdos como inibidores de quinase
DK0841949T3 (da) Anvendelse af saccharid-konjugater
WO2004026246A3 (en) Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
WO2000038665A3 (en) Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
EP1463531A4 (en) PROCESS FOR INHIBITING OKULAR PROCESSES
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
BR0213100A (pt) Combinações para o tratamento de distúrbios imuniinflamatórios
BR9913441A (pt) Derivados do ácido tiazolìnico
WO2007079171A3 (en) Treatment for hodgkin's lymphoma
BR0011225A (pt) Agente para tratar de olhos secos, seu método e uso
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2007079146A8 (en) Treatment for non-hodgkin's lymphoma
BRPI0408491A (pt) tratamento da doença de alzheimer
TR200002626T2 (tr) Terkip
EE200300366A (et) Meetodid nahahaiguste ravimiseks või tõkestamiseks CD2-siduvate vahendite abil
EP1141251A4 (en) CONNECTIONS, SCREENING METHOD AND METHOD OF TREATING DISEASES OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEM
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
ATE338142T1 (de) Methoden zur diagnose und behandlung von herzkrankheiten

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: NEUROCHEM (INTERNATIONAL) LIMITED (CH)

B25G Requested change of headquarter approved

Owner name: NEUROCHEM (INTERNATIONAL) LIMITED (CH)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020050084719/RJ DE 18/08/2005.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/00

Ipc: A61K 31/185 (2009.01), A61K 31/662 (2009.01), A61P

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 10(VIII) E 13 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.